Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium® (SABCS). The company will share the latest advances in the MyRisk® Hereditary Cancer Test that support guideline-driven treatment decisions. Additionally, the company is presenting data on its Precise® Molecular Residual Disease (MRD) Test, an ultrasensitive, second-generation pan-tumor MRD test that is especially impactful for low-tumor-shedding cancers, such as breast cancer. It has high sensitivity and specificity at low tumor fraction.1 “I am thrilled that we are sharing some very strong data at SABCS from multiple breast-cancer studies that used Precise MRD,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Each study showcases the benefit of ultrasensitive and quantitative ctDNA testing, as we observed no
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Why Myriad Genetics (MYGN) Stock Is Trading Lower Today [Yahoo! Finance]Yahoo! Finance
- How Recent Developments Are Shaping the Myriad Genetics Investment Story [Yahoo! Finance]Yahoo! Finance
- Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health [Yahoo! Finance]Yahoo! Finance
- Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast HealthGlobeNewswire
- Myriad Genetics (NASDAQ:MYGN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
MYGN
Earnings
- 11/3/25 - Beat
MYGN
Sec Filings
- 12/12/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- MYGN's page on the SEC website